[HTML][HTML] Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis …
WZ Zhong, HH Yan, KN Chen, C Chen… - Signal transduction and …, 2023 - nature.com
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
[HTML][HTML] Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of …
WZ Zhong, HH Yan, KN Chen, C Chen… - Signal Transduction …, 2023 - ncbi.nlm.nih.gov
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant
non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 …
non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 …
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the …
WZ Zhong, HH Yan, KN Chen, C Chen… - Signal Transduction …, 2023 - search.proquest.com
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the …
WZ Zhong, HH Yan, KN Chen, C Chen… - … & Targeted Therapy, 2023 - search.ebscohost.com
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the …
WZ Zhong, HH Yan, KN Chen… - Signal transduction …, 2023 - pubmed.ncbi.nlm.nih.gov
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the …
WZ Zhong, HH Yan, KN Chen, C Chen… - Signal Transduction …, 2023 - europepmc.org
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the …
WZ Zhong, HH Yan, KN Chen, C Chen… - Signal Transduction …, 2023 - europepmc.org
EMERGING-CTONG 1103 showed improved progression-free survival (PFS) with
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …
neoadjuvant erlotinib vs. chemotherapy for patients harbouring EGFR sensibility mutations …